ABSTRACT
Neuron-derived orphan receptor-1 (NOR-1) is a nuclear receptor recently involved in the onset and development of atherosclerosis. NOR-1 is induced in a cellspecific manner by extracellular stimuli. NOR-1 is overexpressed in human atherosclerotic plaques and in porcine arteries subjected to angioplasty, is induced by growth factors in vascular cells and it has been involved in cell migration and proliferation. This article examines the mechanisms that regulate NOR-1 in vascular cells and the effects of NOR-1 knockdown on cell growth induced by mitogens, in particular thrombin. Mitogenic stimuli upregulates NOR-1 in endothelial cells (ECs) through multiple pathways, including increase of cytosolic calcium, activation of protein kinase C, mitogen-activated protein kinase (MAPK) (ERK1/2 and p38 MAPK) and downstream activation of cAMP response element binding protein (CREB). Inhibition of protease-activated receptor-1 (PAR-1) abolished thrombin-induced NOR-1 up-regulation and DNA synthesis. NOR-1 knockdown reduces DNA synthesis and EC re-growth in an in vitro model of wound repair. NOR-1 could be regarded as a new target to prevent endothelial effects triggered by thrombin and other mitogens.
INTRODUCTION
Endothelial cell (EC) growth is critical in different processes including endothelial repair at sites of spontaneous or iatrogenic disruption and in the formation of new vessels (neovascularization). In these processes ECs migrate and proliferate as a result of the mitogenic stimulus triggered by growth factors and cytokines. This involves the coordinately regulation of multiple genes by a set of transcription factors that control cell cycle entry and other EC functions (1) . Recently, we have identified NOR-1 as an early-response gene in VSMCs and ECs (2-5). NOR-1, together with Nur77 and Nurr1, form the NR4A subfamily of orphan nuclear receptors (NRs). NRs of this subfamily are transcription factors regulated in a cell-specific manner by extracellular stimuli (6) . These genes have emerged as potentially relevant players in the complex network of proteins that regulate vascular cell activation in inflammation and atherogenesis (2) (3) (4) (5) (6) (7) (8) (9) .
In recent years different studies point to thrombin as a key multifunctional serine protease, that besides its well known role in the blood coagulation cascade, activates PARs modulating vascular function (10) . PAR-1, the predominant receptor of thrombin in vascular cells, elicits a variety of responses including regulation of vascular tone, cell migration and proliferation and angiogenesis (10) . In this paper we analyze the molecular mechanisms underlying thrombin-induced EC activation and the role of PAR-1 and NOR-1 in this process.
NOR-1 IN THE VASCULAR WALL

Structure of NOR-1 and regulation of transcriptional activity
NOR-1 belongs to the NR4A subfamily of NRs that consists of three closely related members: Nur77, firstly identified as a gene induced by nerve growth factor (NGF) in the pheocromocytoma cell line PC12 (11); NOR-1, identified by Ohkura et al. (12) in forebrain neural cells undergoing apoptosis, and Nurr1 firstly characterized as a "brain-specific" transcription factor in dopaminergic neurons (13) . These receptors share the typical modular structure of NRs composed by several functional domains, as follows: a variable N-terminal region, containing the ligand-independent activation function-1 (AF-1), responsible for interaction with other transcription factors; a central DNA-binding domain (DBD), and a variable linker region that connects the DBD to the C-terminus containing the ligand-binding domain (LBD) ( Figure 1A) . The most divergent domain in NR4A genes is the Nterminal domain, which could lead to significant qualitative or quantitative differences among them ( Figure 1B) . Although members of the NR4A subfamily have structural features of ligand-activated transcription factors, recent findings suggest that they do not require ligand binding for activation (14) . The transcriptional activity of these genes is largely regulated by extracellular stimuli, which determine their expression level and modulates posttranslational modifications (6).
Regulation of NOR-1 by extracellular stimuli in vascular cells 3.2.1. Regulation of NOR-1 in VSMC
NOR-1 is an immediate-early response gene strongly induced by growth factors in VSMCs (2-4).
Several growth factors commonly involved in atherogenesis, including platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and thrombin significantly induce NOR-1 in human VSMCs. In addition, NOR-1 mRNA levels are up-regulated by compounds that activate specific signalling pathways, such as phorbol-12-myristate-13-acetate (PMA; a PKC activator), A23187 (a calcium ionophore), forskolin (an adenylyl cyclase activator) and the cAMP analogue 8-Br-cAMP. However, the strongest inducers are serum and native low-density lipoproteins (LDL) (2-4), agents that contain bioactive molecules able to activate several cell signalling pathways leading to NOR-1 up-regulation. LDL-induced NOR-1 expression is mediated by early intracellular events, including increase of [Ca 2+ ] i and activation of PKC and MAPK pathways (ERK1/2 and p38 MAPK) (4), via a pertussis toxin (PTX)-sensitive mechanism independent of the classic LDL receptor (3).
Regulation of NOR-1 in endothelial cells
NOR-1 is strikingly induced by growth factors in ECs. In fact, it has been identified as one of the most strongly induced genes by vascular endothelial growth factor (VEGF) in these cells (8) . This effect is produced via VEGF receptor-2 (VEGFR-2), also known as kinase insert domain-containing receptor (KDR), the main receptor mediating VEGF actions in ECs. NOR-1 up-regulation by VEGF is sensitive to ERK1/2, [Ca 2+ ] i , PKC and calcineurin inhibition (5, 8) . By contrast, VEGF-induced expression of NOR-1 is insensitive to rapamycin and to LY2940002, an inhibitor of phosphatidyl-inositol-3-kinase (PI3K) (8) . The signalling mechanisms mediating VEGF regulation of NOR-1 diverge from those responsible for expression of other VEGF-induced genes at level of calcineurin. Interestingly, cyclosporine A, an immunosuppressor drug that acts as a specific inhibitor of calcineurin and potently blocks angiogenesis, inhibited the expression of the three NR4A genes (8) . The transcriptional activation of NOR-1 promoted by VEGF seems to be mediated by the nuclear factor of activated T cells (NFAT), a transcription factor that seems to be critical in Ca 2+ /calcineurin-dependent vascular functions (15) , and by CREB (5).
Modulation of NOR-1 transcription by CREB in vascular cells
The transcription of NOR-1 is highly dependent on CREB. NOR-1 promoter contains three CRE elements near its transcriptional start site that are critical for its transcriptional activation as we and others have extensively analyzed in VSMC and ECs (2) (3) (4) (5) 9) . In these cells CREB activation seems to be a common output for the signal transduction pathways involved in NOR-1 induction. Stimuli that activate CREB, via phosphorylation in Ser 133 , such as serum, PDGF, thrombin, LDL or VEGF strongly induce NOR-1 (2-5,9). By contrast, compounds that interfere with signalling pathways upstream of CREB, such as PKC inhibitors or calcium chelators, inhibit CREB phosphoylation and prevent NOR-1 up-regulation. CREBmediated NOR-1 up-regulation is in agreement with reports that associate CREB activation with proliferation of vascular cells (16, 17) , likely as a result of its active role regulating the expression of several cyclins and cyclindependent kinases involved in cell cycle progression.
Pathophysiological roles of NOR-1 in the vascular wall
NOR-1 as well as Nur77 and Nurr1 have been involved in different cell processes including apoptosis (18), cell differentiation (19) and proliferation (2-5,9). Interestingly, all three genes have been described in human atherosclerotic lesions (2,7), but conflicting results have been reported regarding their role in vascular cell proliferation. Indeed, recent results suggest that NR4A genes could play opposite roles in vascular cell proliferation. NOR-1 inhibition or genetic ablation of NOR-1 reduces the proliferation of vascular cells (2-5,9) while Nur77 over-expression inhibited cell proliferation (7) . Recently, we showed that NOR-1 is up-regulated in active human coronary atherosclerotic lesions (Figure 2A ) and is strongly induced in porcine arteries (both coronaries and carotids) subjected to angioplasty, a mechanical injury process that induces the expression of genes associated with VSMC activation and proliferation such as c-fos, cmyc or c-myb (20) (Figure 2B ). In addition, NOR-1 inhibition by antisense oligonucleotides (ODNs) or small interference RNA (siRNA) significantly prevented proliferation and wound healing induced by growth factors (serum) in VSMC ( Figure 2C and D) (2) and by cytokines (VEGF) in ECs (5). Finally, inhibition of VSMC proliferation by HMG-CoA reductase inhibitors (statins) is associated with the inhibition of NOR-1 up-regulation by a RhoA/Rho-associated kinase [ROCK]-dependent mechanism (4).
MODULATION OF ENDOTHELIAL FUNCTION BY THROMBIN
Endothelial functions modulated by thrombin via PAR-1
Thrombin is a multifunctional serine protease that activates blood platelets and elicits multiple effects on a variety of cell types among them ECs (10, 21) (Figure 3 ). Cellular effects of thrombin are mediated by PARs, members of the G protein-coupled receptors (GPCRs) that carry their own ligand which remain cryptic until unmasked by proteolytic cleavage. Four PARs have been described: PAR-1, -2, -3 and -4. Thrombin seems to be the main physiological activator of PAR-1 and PAR-4, but it can also activate PAR-3, that functions as a cofactor for PAR-4, and is not considered to directly elicit intracellular signalling (22) . Finally, although PAR-2 is not directly activated by thrombin it has been reported that it can be transactivated by thrombin-cleaved PAR-1 (23) . In healthy arteries PARs are mainly expressed in ECs, in particular PAR-1, the main receptor involved in thrombin-mediated effect in ECs. PAR-1 participates in the regulation of vascular tone, vascular permeability, endothelial secretory activity, EC proliferation and angiogenesis (10, 21) . Indeed, the effect of thrombin on different stages of angiogenesis has focused the interest of many investigators in the last years. Thrombin inhibits in a dose-dependent manner EC adhesion, an early event in the angiogenic cascade, through a PAR-1 dependent mechanism (24) . In addition, thrombin activates progelatinase A (matrix metalloproteinase-2 [MMP-2]), which contributes to the local dissolution of basement membrane facilitating migration of activated ECs (25) . PAR-1 has also been involved in thrombin-induced VEGF up-regulation and EC proliferation (26, 27) . Furthermore, different studies have reported that thrombin is able to up-regulate hypoxia-inducible factor 1 alpha (HIF-1α) in vascular cells under non-hypoxic conditions in a reactive oxygen species-dependent manner (27, 28) . To modulate these endothelial functions thrombin alters the expression of an array of genes. Indeed, thrombin up- 
NOR-1 is induced by thrombin and mediates endothelial cell growth 4.2.1. Thrombin induces NOR-1 in endothelial cells via PAR-1
Thrombin up-regulates NOR-1 expression with a similar potency to serum or VEGF. In human ECs thrombin induces NOR-1 expression in a dose-and time-dependent manner (29) . The effect is observed at doses as low as 0.1 U/mL and it is maximal 1 hour after induction. The induction of NOR-1 by thrombin is dependent on PAR-1, thrombin receptor that mediates main biologic responses triggered by thrombin in vascular cells including cell proliferation (10, 21) . Indeed, similarly thrombin-receptor activator peptide-6 (TRAP-6), a PAR-1 agonist, increases NOR-1 mRNA levels in a time-and dose-dependent manner, while a PAR-1 blocking antibody (ATAP-2) (30) prevents such effect (29) . NOR-1 up-regulation by thrombin is mediated by several intracellular pathways, including calcium mobilization and activation of PKC and MAPK pathways (ERK1/2 and p38 MAPKs). PTX significantly reduces the induction of NOR-1 produced by thrombin, according with the nature of PAR-1 as a GPCR that signals, at least in a part, through Galphai proteins. Thrombin-induced NOR-1 up-regulation is also reduced by BAPTA-AM (a calcium chelator), GF10933X (a PKC inhibitor), U0128 (a MEK inhibitor) and SB203580 (a p38 MAPK inhibitor) ( Figure 4A ). These pathways are similar to those involved in NOR-1 induction by growth factors in VSMC and by VEGF in ECs (2-5).
CREB activation is critical in NOR-1 induction by thrombin
The up-regulation of NOR-1 by thrombin is associated to the ability of this protease to promote CREB activation (29) . Those inhibitors that reduced NOR-1 up-regulation induced by thrombin (PTX, BAPTA-AM, GF10933X, U0128 and SB203580) also significantly prevents CREB activation (phosphorylation in Ser133) ( Figure 4B ). In addition, TRAP-6 that mimics the effect of thrombin on NOR-1 expression also promotes CREB activation, while ATAP-2 prevents such effect. Finally, site-directed mutagenesis of the two CRE sites located at -79 and -53 bp respectively upstream the transcription star-site, or co-transfection with a CREB dominant-negative (CREB mutated in Ser133), abolish thrombin-induced NOR-1 promoter activity. The signalling pathways leading to NOR-1 up-regulation by thrombin in ECs are shown in figure 4C. 
NOR-1 modulates thrombin-induced DNA synthesis and cell growth
NOR-1 seems to play a key role as a transcription factor involved in thrombin-induced EC mitogenesis and re-endothelization following a mechanical injury (29) . Certainly, specific inhibition of NOR-1 expression with antisense ODNs (AS-NOR-1) or siRNA (siRNA/NOR-1) significantly prevents thrombin-induced DNA synthesis ( Figure 5A ). The inhibition of NOR-1 expression by these means is as efficient as the direct blockage of PAR-1 (using ATAP-2) preventing thrombin-induced EC DNA synthesis. In addition, inhibition of NOR-1 expression, transfecting ECs with siRNA/NOR-1, prevents thrombin-induced EC re-growth in an in vitro model of wound repair ( Figure 5B ). These results are in agreement with findings suggesting a prominent role of this orphan receptor in VSMC growth using similar approaches (2-5).
SUMMARY AND PERSPECTIVES
Thrombin induces NOR-1 expression in ECs through a mechanism dependent on PAR-1 that involves different signalling pathways leading to CREB activation. The direct inhibition of NOR-1 expression prevented endothelial cell growth induced by thrombin and other mitogens, suggesting that NOR-1 could be a key CREB targeted transcription factor regulating the endothelial cell proliferative response. NOR-1 has emerged as a new player in the complex network of transcription factors that regulate EC growth. Since EC proliferation is a key event in the angiogenic response associated to pathologic processes such as atherosclerosis and cancer, NOR-1 could be regarded as a potential therapeutic target in strategies aimed to prevent cell proliferation.
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